Biotech company, Vgenomics raises seed investment from Mumbai Angels & others

The company plans to utilize the investment for building diagnostics solutions and scaling the existing business with neonatologists, gynaecologists, paediatricians, and clinical geneticists.

0
113
New Delhi: Mumbai Angels, India’s premier platform for early-stage investments, now a part of 360 ONE, has further expanded its portfolio through its latest investment in Vgenomics India.
In a significant stride forward for biotechnology and healthcare, Vgenomics, the startup has successfully closed its seed investment round, led by Mumbai Angels and O2 Angel Network. The round also drew enthusiastic participation from prominent Angel investors like Rohit Chanana, Sabine Kapasi, among others.
The company plans to utilize the investment for building diagnostics solutions and scaling the existing business with neonatologists, gynaecologists, paediatricians, and clinical geneticists. This infusion of capital not only endorses their groundbreaking approach but also sets the stage for accelerated development and deployment of their solutions, targeting a staggering 175 million children worldwide afflicted with rare diseases.
Vgenomics is utilizing next-generation sequencing technologies to develop diagnostics and therapeutics for rare diseases that affect children; these are diseases that are present at birth and are often caused by alterations in the DNA. Leveraging genomics and artificial intelligence they are bringing novel solutions to market for 175 M+ children suffering from rare diseases across the world.
Nandini Mansinghka, CEO of Mumbai Angels shared her thoughts. “Vgenomics’ groundbreaking approach to harnessing next-generation, AI -powered sequencing technologies to address rare diseases is commendable. We believe this investment not only validates their innovative strategy but also propels the journey towards impacting the lives of millions of children affected by rare diseases worldwide.”
Rahila Sardar, Founder and CEO, Vgenomics, said “This marks a pivotal advancement in our journey, underscoring the necessity of a scientific strategy tailored for rare diseases. This will help us in uniting organizations dedicated to rare diseases, and establish Vgenomics as the one-stop hub for rare disease solutions”
Preeti Gupta Lal, Co-Founder and CSO at Vgenomics shared “We express our sincere gratitude to our investors for their confidence in Vgenomics. This investment validates our approach and will help us focus on using the next-generation sequencing technologies and machine learning, to develop diagnostics and drugs for rare diseases specific for the Indian population.”
A team of distinguished women scientists, with a cumulative experience of over 35 years founded Vgenomics in 2022. The team is united by a mission: to pioneer innovative solutions for rare diseases and transform the lives of children affected by these conditions.
These conditions, though rare individually, are prevalent, particularly in India with an estimated 100 million patients as per IORD (Indian Organization for Rare Diseases).
Rare diseases take an average of 7 years to diagnose, while development of treatments takes 10 to 15 years. Vgenomics is building proprietary tools that will bring diagnostic and therapeutic solutions for multiple rare diseases, decreasing the time of diagnosis and therapeutics development by 80%.
Vgenomics generates revenue from customers that include renowned researchers and clinicians from AIIMS, PGIMER, Dr. Shroff etc. They have received accolades from industry partners, including the prestigious Illumina Grant.